X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PFIZER - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PFIZER CIPLA/
PFIZER
 
P/E (TTM) x 43.5 23.8 182.8% View Chart
P/BV x 3.6 3.8 94.8% View Chart
Dividend Yield % 0.4 0.9 41.8%  

Financials

 CIPLA   PFIZER
EQUITY SHARE DATA
    CIPLA
Mar-17
PFIZER
Mar-16
CIPLA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6222,724 22.8%   
Low Rs4581,611 28.4%   
Sales per share (Unadj.) Rs181.9440.9 41.2%  
Earnings per share (Unadj.) Rs12.948.7 26.4%  
Cash flow per share (Unadj.) Rs29.375.8 38.7%  
Dividends per share (Unadj.) Rs2.0015.00 13.3%  
Dividend yield (eoy) %0.40.7 53.5%  
Book value per share (Unadj.) Rs155.7462.9 33.6%  
Shares outstanding (eoy) m804.5145.75 1,758.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.9 60.4%   
Avg P/E ratio x42.044.5 94.3%  
P/CF ratio (eoy) x18.428.6 64.4%  
Price / Book Value ratio x3.54.7 74.1%  
Dividend payout %15.530.8 50.4%   
Avg Mkt Cap Rs m434,51699,163 438.2%   
No. of employees `00023.02.9 797.6%   
Total wages/salary Rs m26,3382,758 955.1%   
Avg. sales/employee Rs Th6,349.16,981.7 90.9%   
Avg. wages/employee Rs Th1,143.0954.5 119.8%   
Avg. net profit/employee Rs Th449.3771.1 58.3%   
INCOME DATA
Net Sales Rs m146,30220,170 725.3%  
Other income Rs m2,287857 266.7%   
Total revenues Rs m148,58921,028 706.6%   
Gross profit Rs m24,7584,310 574.5%  
Depreciation Rs m13,2291,239 1,068.0%   
Interest Rs m1,5945 30,650.0%   
Profit before tax Rs m12,2223,923 311.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m1,7981,794 100.2%   
Profit after tax Rs m10,3542,228 464.8%  
Gross profit margin %16.921.4 79.2%  
Effective tax rate %14.745.7 32.2%   
Net profit margin %7.111.0 64.1%  
BALANCE SHEET DATA
Current assets Rs m87,37016,299 536.1%   
Current liabilities Rs m33,0817,594 435.6%   
Net working cap to sales %37.143.2 86.0%  
Current ratio x2.62.1 123.1%  
Inventory Days Days8765 133.2%  
Debtors Days Days6226 242.0%  
Net fixed assets Rs m111,5678,622 1,294.0%   
Share capital Rs m1,609458 351.7%   
"Free" reserves Rs m123,64520,722 596.7%   
Net worth Rs m125,25421,180 591.4%   
Long term debt Rs m36,45425 145,814.4%   
Total assets Rs m209,53229,137 719.1%  
Interest coverage x8.7755.5 1.1%   
Debt to equity ratio x0.30 24,656.5%  
Sales to assets ratio x0.70.7 100.9%   
Return on assets %5.77.7 74.4%  
Return on equity %8.310.5 78.6%  
Return on capital %8.519.0 44.8%  
Exports to sales %34.20.1 57,501.4%   
Imports to sales %8.317.5 47.7%   
Exports (fob) Rs m50,05012 417,080.8%   
Imports (cif) Rs m12,2033,526 346.1%   
Fx inflow Rs m51,06652 98,869.9%   
Fx outflow Rs m17,678140 12,628.9%   
Net fx Rs m33,388-88 -37,799.5%   
CASH FLOW
From Operations Rs m23,8243,436 693.3%  
From Investments Rs m-13,127-6,991 187.8%  
From Financial Activity Rs m-13,239-619 2,139.4%  
Net Cashflow Rs m-2,478-4,174 59.4%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 63.9 32.6%  
Indian inst/Mut Fund % 12.2 7.5 162.7%  
FIIs % 23.7 4.9 483.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.7 110.5%  
Shareholders   161,166 85,207 189.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FDC LTD.  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 22, 2017 (Close)

TRACK CIPLA

CIPLA - DR. DATSONS LABS COMPARISON

COMPARE CIPLA WITH

MARKET STATS